^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    6MW3211

    i
    Other names: 6MW3211
    Associations

    News

    Trials
    Company:
    Mabwell (Shanghai) Biosci
    Drug class:
    PD-L1 inhibitor, CD47 inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost2years
    A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P2a, N=36, Not yet recruiting, Mabwell (Shanghai) Bioscience Co., Ltd.
    New P2a trial
    |
    EGFR (Epidermal growth factor receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    6MW3211